RxDoctor Payments Data

Peter Tan, MD

Internal Medicine · Arcadia, CANPI 1144228909

Payments from drug & device makers

$1,922in general payments, 2019–2025

Across 74 payments — averaging $25.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$326
  • Amgen$260
  • Boehringer Ingelheim$213
  • Novo Nordisk$178
  • Bayer$175
  • Pfizer$154
  • plus $615 from 10 others

What the payments were for

  • Food & beverage$1,922100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,922 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$185,690
Medicare patients
336
Services billed
1,842

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin116$98,221
FarxigaDapagliflozin Propanediol107$75,992
JanuviaSitagliptin Phosphate84$48,051
EliquisApixaban49$32,854
VascepaIcosapent Ethyl89$31,298
KerendiaFinerenone20$19,240
JanumetSitagliptin Phos/Metformin Hcl29$18,616
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$16,313
VemlidyTenofovir Alafenamide11$16,002
LinzessLinaclotide29$15,783
Janumet XrSitagliptin Phos/Metformin Hcl20$12,745
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,595
Cyclosporine21$8,101
Spiriva RespimatTiotropium Bromide15$7,910
Breo ElliptaFluticasone/Vilanterol20$7,311

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat$213$106,130131 claims
MerckJanuvia, Janumet, Janumet Xr$101$79,412133 claims
AstraZenecaFarxiga$326$75,992107 claims
PfizerEliquis, Paxlovid$154$34,28482 claims
BayerKerendia$175$19,24020 claims
GSKTrelegy Ellipta, Breo Ellipta$129$15,90631 claims
AbbVieLinzess$74$15,78329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Arcadia

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →